In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells

Journal of the Neurological Sciences

Volumn 346, Issue 1-2, 2014, Pages 66-74

  Kelland, Eve E ^a   Gilmore, Wendy ^a   Hayardeny, Liat ^b   Weiner, Leslie P ^a   Lund, Brett T ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

Laquinimod; Multiple sclerosis; Neural stem cell; Oligodendrocyte progenitor cell

Indexed keywords

LAQUINIMOD; CYTOKINE; NERVE PROTEIN; QUINOLONE DERIVATIVE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE SCLEROSIS; NEURAL STEM CELL; OLIGODENDROCYTE PRECURSOR CELL; BRAIN; CELL MOTION; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; EMBRYONIC STEM CELL; GENE EXPRESSION REGULATION; METABOLISM; NERVE CELL; NONPARAMETRIC TEST; OLIGODENDROGLIA; TIME; TRANSFORMED CELL LINE;

BRAIN; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; NEURONS; OLIGODENDROGLIA; QUINOLONES; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84911007685     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.07.058     Document Type: Article

References (42)

1. R. Aharoni, R. Saada, R. Eilam, L. Hayardeny, M. Sela, and R. Arnon Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis J Neuroimmunol 251 2012 14 24
2. J.C. Biancotti, S. Kumar, and J. de Vellis Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair Neurochem Res 33 2008 2615 2628
3. A. Boyd, H. Zhang, and A. Williams Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models Acta Neuropathol 125 2013 841 859
4. W. Bruck, R. Pfortner, T. Pham, J. Zhang, L. Hayardeny, and V. Piryatinsky Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination Acta Neuropathol 124 2012 411 424
5. W. Bruck, and C. Wegner Insight into the mechanism of laquinimod action J Neurol Sci 306 2011 173 179
6. C. Brunmark, A. Runstrom, L. Ohlsson, B. Sparre, T. Brodin, and M. Astrom The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis J Neuroimmunol 130 2002 163 172
7. K.S. Carbajal, J.L. Miranda, M.R. Tsukamoto, and T.E. Lane CXCR4 signaling regulates remyelination by endogenous oligodendrocyte progenitor cells in a viral model of demyelination Glia 59 2011 1813 1821
8. K.S. Carbajal, C. Schaumburg, R. Strieter, J. Kane, and T.E. Lane Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis Proc Natl Acad Sci U S A 107 2010 11068 11073
9. A. Chang, A. Nishiyama, J. Peterson, J. Prineas, and B.D. Trapp NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions J Neurosci 20 2000 6404 6412
10. G. Comi, D. Jeffery, L. Kappos, X. Montalban, A. Boyko, and M.A. Rocca Placebo-controlled trial of oral laquinimod for multiple sclerosis N Engl J Med 366 2012 1000 1009
11. G. Comi, A. Pulizzi, M. Rovaris, O. Abramsky, T. Arbizu, and A. Boiko Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 371 2008 2085 2092
12. S. Falahati, M. Breu, A.T. Waickman, A.W. Phillips, E.J. Arauz, and S. Snyder Ischemia-induced neuroinflammation is associated with disrupted development of oligodendrocyte progenitors in a model of periventricular leukomalacia Dev Neurosci 35 2-3 2013 182 196
13. S.P. Fancy, J.R. Chan, S.E. Baranzini, R.J. Franklin, and D.H. Rowitch Myelin regeneration: a recapitulation of development? Annu Rev Neurosci 34 2011 21 43
14. A.K. Foote, and W.F. Blakemore Inflammation stimulates remyelination in areas of chronic demyelination Brain 128 2005 528 539
15. R.J. Franklin, and C. Ffrench-Constant Remyelination in the CNS: from biology to therapy Nat Rev Neurosci 9 2008 839 855
16. N. Grytten, S.B. Glad, J.H. Aarseth, H. Nyland, R. Midgard, and K.M. Myhr A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway Neurology 66 2006 182 186
17. M. Gurevich, T. Gritzman, R. Orbach, T. Tuller, A. Feldman, and A. Achiron Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study J Neuroimmunol 221 2010 87 94
18. W.J. Hader, and I.M. Yee Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan Neurology 69 2007 1224 1229
19. H. Houzen, M. Niino, M. Hirotani, T. Fukazawa, S. Kikuchi, and K. Tanaka Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan J Neurol Sci 323 2012 117 122
20. K.H. Jones, and J.A. Senft An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide J Histochem Cytochem 33 1985 77 79
21. E.E. Kelland, W. Gilmore, L.P. Weiner, and B.T. Lund The dual role of CXCL8 in human CNS stem cell function: multipotent neural stem cell death and oligodendrocyte progenitor cell chemotaxis Glia 59 2011 1864 1878
22. E.E. Kelland, and N.J. Toms Group I metabotropic glutamate receptors limit AMPA receptor-mediated oligodendrocyte progenitor cell death Eur J Pharmacol 424 2001 R3 R4
23. B.T. Lund, N. Ashikian, H.Q. Ta, Y. Chakryan, K. Manoukian, and S. Groshen Increased CXCL8 (IL-8) expression in multiple sclerosis J Neuroimmunol 155 2004 161 171
24. R.A. Marrie, N. Yu, J. Blanchard, S. Leung, and L. Elliott The rising prevalence and changing age distribution of multiple sclerosis in Manitoba Neurology 74 2010 465 471
25. M.K. Mishra, J. Wang, C. Silva, M. Mack, and V.W. Yong Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod Am J Pathol 181 2012 642 651
26. S. Moore, A.J. Khalaj, J. Yoon, R. Patel, G. Hannsun, and T. Yoo Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis Brain Behav 3 2013 664 682
27. B. Nash, C.E. Thomson, C. Linington, A.T. Arthur, J.D. McClure, and M.W. McBride Functional duality of astrocytes in myelination J Neurosci 31 2011 13028 13038
28. J.H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B.G. Weinshenker Multiple sclerosis N Engl J Med 343 2000 938 952
29. K.M. Omari, S.E. Lutz, L. Santambrogio, S.A. Lira, and C.S. Raine Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1 Am J Pathol 174 2009 164 176
30. J.W. Prineas, R.O. Barnard, E.E. Kwon, L.R. Sharer, and E.S. Cho Multiple sclerosis: remyelination of nascent lesions Ann Neurol 33 1993 137 151
31. M. Pugliatti, T. Riise, M.A. Sotgiu, S. Sotgiu, W.M. Satta, and L. Mannu Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia Neuroepidemiology 25 2005 129 134
32. A. Runstrom, T. Leanderson, L. Ohlsson, and B. Axelsson Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice J Neuroimmunol 173 2006 69 78
33. U. Schulze-Topphoff, A. Shetty, M. Varrin-Doyer, N. Molnarfi, S.A. Sagan, and R.A. Sobel Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity PLoS One 7 2012 e33797
34. A. Setzu, J.D. Lathia, C. Zhao, K. Wells, M.S. Rao, and C. Ffrench-Constant Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells Glia 54 2006 297 303
35. H. Snethen, S. Love, and N. Scolding Disease-responsive neural precursor cells are present in multiple sclerosis lesions Regen Med 3 2008 835 847
36. J. Thone, G. Ellrichmann, S. Seubert, I. Peruga, D.H. Lee, and R. Conrad Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor Am J Pathol 180 2012 267 274
37. E. Toubi, S. Nussbaum, E. Staun-Ram, A. Snir, D. Melamed, and L. Hayardeny Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis J Neuroimmunol 251 2012 45 54
38. B.D. Trapp, and K.A. Nave Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31 2008 247 269
39. C. Wegner, C. Stadelmann, R. Pfortner, E. Raymond, S. Feigelson, and R. Alon Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis J Neuroimmunol 227 2010 133 143
40. G. Wolswijk Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord Brain 125 2002 338 349
41. J.S. Yang, L.Y. Xu, B.G. Xiao, G. Hedlund, and H. Link Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats J Neuroimmunol 156 2004 3 9
42. S.C. Zhang, M. Wernig, I.D. Duncan, O. Brustle, and J.A. Thomson In vitro differentiation of transplantable neural precursors from human embryonic stem cells Nat Biotechnol 19 2001 1129 1133